CJC-1295 No DAC (Mod GRF 1-29): Complete Guide

CJC-1295 without DAC is the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-44), with four amino acid substitutions at positions 2, 8, 15, and 27 that protect the molecule from rapid enzymatic breakdown. The original GHRH 1-29 fragment (sermorelin) has a plasma half-life of less than 10 minutes because dipeptidyl peptidase IV (DPP-IV) chews through it almost immediately after injection. The four substitutions in mod GRF 1-29 extend the half-life to approximately 30 minutes, long enough for a meaningful growth hormone pulse without the continuous elevation that DAC-conjugated versions produce (Ionescu & Bhatt, Endotext, 2022).

Think of it like a match versus a candle. Sermorelin is the match: it flares bright and dies in seconds. Mod GRF 1-29 is a short candle: it burns long enough to light the room, then goes out. CJC-1295 with DAC is an oil lamp: it stays lit for days. Your pituitary gland responds differently to each pattern, and that difference determines whether the resulting growth hormone release looks natural or artificial.

The four amino acid substitutions are: Ala at position 2 (replacing Asp), Gln at position 8 (replacing Asn), Ala at position 15 (replacing Gly), and Leu at position 27 (replacing Met). These changes block the two primary cleavage sites that degrade native GHRH without altering the peptide's binding affinity for the GHRH receptor on pituitary somatotroph cells (Tauber et al., Growth Horm IGF Res, 1999).

The "DAC" stands for Drug Affinity Complex, a lysine-linked maleimidopropionic acid group that binds covalently to serum albumin after injection. This albumin binding extends the peptide's half-life from 30 minutes to approximately 6-8 days. That single chemical modification creates a fundamentally different pharmacological profile.

The clinical study by Teichman et al. demonstrated that CJC-1295 with DAC produced dose-dependent increases in mean GH concentrations of 2-10 fold and IGF-1 increases of 1.5-3 fold after a single subcutaneous injection, with effects lasting 6-14 days (Teichman et al., J Clin Endocrinol Metab, 2006). That sustained elevation is convenient for users who dislike frequent injections. But it comes with a trade-off.

Your pituitary gland is designed to release growth hormone in sharp pulses, not steady streams. The largest natural GH pulse occurs during the first 90 minutes of deep sleep. Smaller pulses follow exercise and fasting. Between these pulses, GH drops to near-zero, which allows somatostatin (the GH-inhibiting hormone) to reset the system for the next burst. CJC-1295 with DAC disrupts this rhythm by keeping the GHRH signal active around the clock.

The no-DAC version preserves the pulsatile pattern. You inject, your pituitary fires a GH pulse, GH returns to baseline within 2 hours, and the system resets. This is why most practitioners and researchers who prioritize physiological GH signaling choose the no-DAC variant for daily protocols. For a broader comparison of GH secretagogues, see the peptide stacking guide.

A common mistake is assuming that more growth hormone circulating for longer equals better results. The biology is more nuanced. The pattern of GH release determines which downstream effects dominate.

Pulsatile GH release activates the JAK2-STAT5 signaling pathway in liver and peripheral tissues. This pathway drives the production of IGF-1, the mediator responsible for most of GH's anabolic and lipolytic effects. Continuous GH exposure, by contrast, desensitizes the JAK2-STAT5 pathway and shifts signaling toward the STAT1 and STAT3 pathways, which are associated with inflammation and insulin resistance rather than tissue growth (Choi & Bhatt, Growth Horm IGF Res, 2007).

Picture a doorbell. Press it once and the person inside gets up to answer. Press it continuously and they stop responding. Pulsatile GH works like a doorbell: each pulse triggers a fresh downstream response. Sustained GH works like holding the button down: the initial signal is strong, but receptor internalization and downstream desensitization progressively blunt the response.

Ho et al. demonstrated this directly in humans. Pulsatile GH infusion produced significantly greater nitrogen retention (a marker of protein synthesis) and lipolysis compared to continuous GH infusion delivering the same total daily dose (Ho et al., J Clin Endocrinol Metab, 1991). The pulse pattern, not the total dose, drove the superior outcome. This finding is the pharmacological foundation for choosing CJC-1295 without DAC over the DAC-conjugated version when the goal is body composition improvement.

For users interested in the GH-fat loss connection, see sermorelin for fat loss and tesamorelin dosage for fat loss.

All dosages below assume subcutaneous injection on an empty stomach (90+ minutes after eating, 30+ minutes before eating). Food intake, particularly carbohydrates, raises insulin and suppresses the GH pulse by up to 80% (Nass et al., J Clin Endocrinol Metab, 2008).

The mod GRF 1-29 + ipamorelin combination is the most popular GH secretagogue stack for a reason. It exploits a fundamental principle of endocrinology: GHRH and GHRPs activate two separate intracellular pathways that converge on the same outcome (GH release), and their combined effect is synergistic rather than additive.

Mod GRF 1-29 binds the GHRH receptor on pituitary somatotroph cells, activating adenylate cyclase and raising intracellular cyclic AMP. Ipamorelin binds the ghrelin receptor (GHS-R1a) on the same cells, activating phospholipase C and raising intracellular calcium. Both signals converge on the exocytosis of stored GH granules. Because the two pathways use different second messengers, stimulating both simultaneously produces a GH pulse far larger than stimulating either alone.

Bowers et al. demonstrated this synergy directly in human subjects. The GH response to combined GHRH + GHRP administration was 3-5 fold greater than the response to either compound alone, and the effect was supra-additive: 1 + 1 equaled 5, not 2 (Bowers et al., J Clin Endocrinol Metab, 1990).

Why ipamorelin specifically? Among the GHRPs (hexarelin, GHRP-2, GHRP-6, ipamorelin), ipamorelin is the only one that produces selective GH release without raising cortisol, prolactin, or aldosterone at standard doses (Raun et al., Eur J Endocrinol, 1998). It also shows minimal receptor desensitization, allowing indefinite use. This selectivity makes it the ideal pairing for a daily GHRH protocol that you plan to run for months.

The practical protocol: - Draw both peptides into the same syringe (they are chemically compatible in bacteriostatic water) - 100 mcg mod GRF 1-29 + 100-200 mcg ipamorelin per injection - 2-3 injections daily (fasted AM, post-workout, before bed) - Cycle: 12-16 weeks on, 4 weeks off

Check your planned combination with the Peptide Interaction Checker and use the Peptide Stack Calculator to build a complete protocol.

Two errors account for most failed mod GRF 1-29 protocols. Both are avoidable with basic knowledge.

Mistake 1: Injecting after a meal. You eat dinner at 7 PM, inject mod GRF 1-29 + ipamorelin at 7:45 PM, and wonder why your sleep quality does not improve. Here is the math. Insulin levels after a carbohydrate-containing meal suppress GH release by 50-80%. If a properly timed injection produces a GH peak of 30 ng/mL, that same injection 45 minutes after dinner produces 6-15 ng/mL. Over 12 weeks, that is the difference between visible body composition changes and nothing measurable. The fix is simple: wait 90 minutes after eating, or inject before bed after a 2-3 hour dinner gap.

Mistake 2: Confusing CJC-1295 with DAC for the no-DAC version. A user buys "CJC-1295" without reading the label, injects 100 mcg three times daily, and ends up with continuously elevated GH for days. The DAC version has a half-life of 6-8 days. Three daily injections of CJC-1295 with DAC stack on top of each other, producing sustained supraphysiological GH levels that cause water retention, joint pain, carpal tunnel symptoms, and insulin resistance. The no-DAC version clears in 2 hours. Verify the label says "Modified GRF 1-29" or "CJC-1295 no DAC" before loading your syringe.

Mistake 3: Running too high a dose of mod GRF 1-29. Some users inject 200-300 mcg per shot, reasoning that more GHRH means more GH. Above 100 mcg, the dose-response curve flattens while side effects (flushing, headache, dizziness) increase proportionally. The receptor has a saturation point. Hitting it harder does not open it wider. The correct strategy is adding a GHRP (ipamorelin) to hit a second receptor, not doubling the dose on the first one.

For a complete overview of common peptide errors, see the peptide safety guide.

Mod GRF 1-29 arrives as a white lyophilized powder, typically in 2 mg or 5 mg vials. You must dissolve it in bacteriostatic water before injection.

Recommended reconstitution for a 2 mg vial: - Add 2 mL bacteriostatic water for a concentration of 1 mg/mL (1,000 mcg/mL) - 100 mcg dose = 0.10 mL = 10 units on a U-100 insulin syringe

Recommended reconstitution for a 5 mg vial: - Add 2.5 mL bacteriostatic water for a concentration of 2 mg/mL (2,000 mcg/mL) - 100 mcg dose = 0.05 mL = 5 units on a U-100 insulin syringe

Step-by-step: 1. Clean both stoppers. Wipe the rubber tops of the peptide vial and bacteriostatic water vial with separate alcohol swabs. 2. Draw the water. Pull 2 mL (or 2.5 mL for the 5 mg vial) of bacteriostatic water into an insulin syringe or a larger syringe with a 25-27 gauge needle. 3. Inject slowly along the glass wall. Aim the stream at the inside wall of the peptide vial, not directly onto the powder. Direct pressure can denature the peptide. 4. Let it dissolve. Wait 2-3 minutes. Gently roll the vial between your palms if any powder remains. Never shake. 5. Label the vial. Write the date, concentration, and peptide name on a piece of tape. 6. Refrigerate immediately. Store at 2-8 degrees C (36-46 degrees F). Use within 28 days.

If you are also reconstituting ipamorelin, keep the vials separate. Draw from each vial into the same syringe at injection time. For exact calculations across any vial size, use our peptide reconstitution calculator. For storage guidelines, see how to store peptides and how long do reconstituted peptides last.

Half-life determines everything about a GHRH analog's dosing schedule, GH release pattern, and clinical utility. This table maps the full spectrum from the shortest-lived to the longest.

The 30-minute half-life of mod GRF 1-29 sits in a pharmacological sweet spot. It is long enough to produce a robust GH pulse (peak GH occurs 15-30 minutes post-injection and returns to baseline within 2 hours) but short enough that the peptide clears before the next natural GHRH pulse from your hypothalamus. This means the feedback loop stays intact. Somatostatin can reset between injections, keeping the pituitary sensitive to each subsequent dose.

Borges et al. confirmed that repeated subcutaneous injections of GHRH analogs with short half-lives maintain GH responsiveness over extended protocols without evidence of tachyphylaxis, provided injections are spaced to allow somatostatin rebound (Borges et al., Neuroendocrinology, 1999). This absence of desensitization is the primary clinical advantage over both longer-acting GHRH analogs and potent GHRPs like hexarelin.

For real-time half-life tracking across your entire peptide protocol, use the peptide half-life tracker.

Mod GRF 1-29 has one of the mildest side effect profiles among GH-stimulating peptides. Because it works through the natural GHRH receptor and the resulting GH release is self-limited by somatostatin feedback, the risk of supraphysiological GH exposure is low when dosed correctly.

Mod GRF 1-29 is a versatile compound, but it is not the right tool for every goal.

Mistake 1: Buying the wrong compound. Vendors frequently mislabel CJC-1295. Some sell the DAC version labeled as "CJC-1295" without specifying which variant it is. Others sell sermorelin (GRF 1-29 without the four protective substitutions) and call it mod GRF 1-29. Always verify the peptide name includes "Modified GRF 1-29" or "tetrasubstituted GRF 1-29" on the certificate of analysis. The difference in half-life (10 minutes for sermorelin vs. 30 minutes for mod GRF vs. 8 days for DAC) means the wrong compound at the wrong dose produces a fundamentally different result.

Mistake 2: Injecting on a full stomach. This is the single most common protocol failure. Insulin is the GH brake. Eating 45 minutes before injection can suppress the GH pulse by 50-80%, turning a $200/month protocol into a $200/month placebo. The 90-minute pre-injection fast is not a suggestion. It is a pharmacological requirement (Nass et al., J Clin Endocrinol Metab, 2008).

Mistake 3: Storing improperly. Reconstituted mod GRF 1-29 left at room temperature degrades rapidly. Within 48 hours outside the refrigerator, potency drops by 20-40%. After a week, the vial is essentially bacteriostatic water. Refrigerate immediately after reconstitution and use within 28 days. For full storage protocols, see how to store peptides.

Mistake 4: Expecting GLP-1-level weight loss. Mod GRF 1-29 enhances GH-driven lipolysis. It does not suppress appetite or create a caloric deficit. Users who expect tirzepatide-like results (15-22% body weight loss) will be disappointed. Realistic expectations: improved body recomposition (simultaneous fat loss and lean mass preservation), better sleep, and faster recovery over 12-16 weeks. For GLP-1 comparison, see semaglutide before and after.